158 related articles for article (PubMed ID: 20565756)
1. Co-lethality studied as an asset against viral drug escape: the HIV protease case.
Brouillet S; Valere T; Ollivier E; Marsan L; Vanet A
Biol Direct; 2010 Jun; 5():40. PubMed ID: 20565756
[TBL] [Abstract][Full Text] [Related]
2. Synthetic lethals in HIV: ways to avoid drug resistance : Running title: Preventing HIV resistance.
Petitjean M; Badel A; Veitia RA; Vanet A
Biol Direct; 2015 Apr; 10():17. PubMed ID: 25888435
[TBL] [Abstract][Full Text] [Related]
3. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
4. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
5. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
Vasavi CS; Tamizhselvi R; Munusami P
J Mol Graph Model; 2017 Aug; 75():390-402. PubMed ID: 28645089
[TBL] [Abstract][Full Text] [Related]
6. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
Su CT; Ling WL; Lua WH; Haw YX; Gan SK
BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
[TBL] [Abstract][Full Text] [Related]
8. The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence.
Van Marck H; Dierynck I; Kraus G; Hallenberger S; Pattery T; Muyldermans G; Geeraert L; Borozdina L; Bonesteel R; Aston C; Shaw E; Chen Q; Martinez C; Koka V; Lee J; Chi E; de Béthune MP; Hertogs K
J Virol; 2009 Sep; 83(18):9512-20. PubMed ID: 19587054
[TBL] [Abstract][Full Text] [Related]
9. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
10. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
11. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
Perryman AL; Lin JH; McCammon JA
Protein Sci; 2004 Apr; 13(4):1108-23. PubMed ID: 15044738
[TBL] [Abstract][Full Text] [Related]
13. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
Pingen M; Wensing AM; Fransen K; De Bel A; de Jong D; Hoepelman AI; Magiorkinis E; Paraskevis D; Lunar MM; Poljak M; Nijhuis M; Boucher CA;
Retrovirology; 2014 Nov; 11():105. PubMed ID: 25575025
[TBL] [Abstract][Full Text] [Related]
14. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.
Jinnopat P; Isarangkura-na-ayuthaya P; Utachee P; Kitagawa Y; de Silva UC; Siripanyaphinyo U; Kameoka Y; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
J Acquir Immune Defic Syndr; 2009 Nov; 52(3):320-8. PubMed ID: 19727001
[TBL] [Abstract][Full Text] [Related]
15. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
[TBL] [Abstract][Full Text] [Related]
16. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
C S V; Tamizhselvi R; Munusami P
J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
[TBL] [Abstract][Full Text] [Related]
17. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Velazquez-Campoy A; Vega S; Freire E
Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
[TBL] [Abstract][Full Text] [Related]
18. Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region.
Kozísek M; Sasková KG; Rezácová P; Brynda J; van Maarseveen NM; De Jong D; Boucher CA; Kagan RM; Nijhuis M; Konvalinka J
J Virol; 2008 Jun; 82(12):5869-78. PubMed ID: 18400858
[TBL] [Abstract][Full Text] [Related]
19. Insights into a mutation-assisted lateral drug escape mechanism from the HIV-1 protease active site.
Sadiq SK; Wan S; Coveney PV
Biochemistry; 2007 Dec; 46(51):14865-77. PubMed ID: 18052195
[TBL] [Abstract][Full Text] [Related]
20. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
